IFN-κ suppresses the replication of influenza A viruses through the IFNAR-MAPK-Fos-CHD6 axis

IFN-κ suppresses the replication of influenza A viruses through the IFNAR-MAPK-Fos-CHD6 axis
复制标题

IFN-γ通过IFNAR-MAPK-Fos-CHD6轴抑制甲型流感病毒的复制。

DOI:
10.1126/scisignal.aaz3381
复制
发表时间:
2020-04-07
期刊:
影响因子:
7.3
通讯作者:
Xu, Jianqing
Xu, Jianqing
中科院分区:
生物学1区
文献类型:
--
作者:
He, Yongquan;Fu, Weihui;Xu, Jianqing

文献摘要

被引文献

相似文献

I型干扰素(IFN)是抵抗病毒感染的第一道防线。使用甲型流感病毒感染的小鼠模型,我们发现IFN-κ是感染H9 N2(一种低致病性甲型禽流感病毒)后最早响应的I型IFN之一,而这种早期诱导在感染引起禽流感的H7N9病毒后不会发生。IFN-κ在培养的人肺细胞中有效地抑制各种流感病毒的复制,并且染色体结构域解旋酶DNA结合蛋白6(chromodomain helicase DNA binding protein 6,CHD 6)是IFN-κ的抗病毒活性的主要效应物,但不是IFN-α或IFN-β的抗病毒活性的主要效应物。CHD 6的诱导需要I型IFN受体亚基IFNAR 1和IFNAR 2、促分裂原活化蛋白激酶(MAPK)p38和转录因子c-Fos,但不依赖于信号转导和转录激活因子1(STAT 1)活性。此外,我们发现,用IFN-κ预处理保护小鼠免受致命的流感病毒攻击。总之,我们的研究结果确定了一个IFN-kappa特异性途径,限制甲型流感病毒,并提供证据表明,IFN-kappa可能有潜力作为预防和治疗剂对甲型流感病毒。
Type I interferons (IFNs) are the first line of defense against viral infection. Using a mouse model of influenza A virus infection, we found that IFN-kappa was one of the earliest responding type I IFNs after infection with H9N2, a low-pathogenic avian influenza A virus, whereas this early induction did not occur upon infection with the epidemic-causing H7N9 virus. IFN-kappa efficiently suppressed the replication of various influenza viruses in cultured human lung cells, and chromodomain helicase DNA binding protein 6 (CHD6) was the major effector for the antiviral activity of IFN-kappa, but not for that of IFN-alpha or IFN-beta. The induction of CHD6 required both of the type I IFN receptor subunits IFNAR1 and IFNAR2, the mitogen-activated protein kinase (MAPK) p38, and the transcription factor c-Fos but was independent of signal transducer and activator of transcription 1 (STAT1) activity. In addition, we showed that pretreatment with IFN-kappa protected mice from lethal influenza viral challenge. Together, our findings identify an IFN-kappa-specific pathway that constrains influenza A virus and provide evidence that IFN-kappa may have potential as a preventative and therapeutic agent against influenza A virus.